GO:0061590 calcium activated phosphatidylcholine scrambling: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061590 describes the calcium-triggered movement of phosphatidylcholine molecules from one leaflet of the plasma membrane to the opposite leaflet.
• This scrambling process disrupts the normal asymmetric distribution of phospholipids across the bilayer and is a hallmark of activated platelets, erythrocytes, and lymphocytes.
• TMEM16F (ANO6) is a principal calcium-activated phospholipid scramblase responsible for phosphatidylcholine scrambling at the plasma membrane.
• Defective calcium-activated phosphatidylcholine scrambling underlies Scott syndrome, a rare bleeding disorder linked to impaired phosphatidylserine exposure.
• Cell-based scrambling assays using fluorescent phospholipid analogs enable quantitative measurement of headgroup preference and calcium sensitivity.
• CRISPR knockout, point-mutation, and knock-in models of TMEM16F and related genes are essential for dissecting the molecular basis of this process.
Description
Calcium activated phosphatidylcholine scrambling (GO:0061590) is a biological process in which phosphatidylcholine molecules move bidirectionally across the plasma membrane bilayer in response to a calcium stimulus. This activity collapses the normal transverse asymmetry of the membrane, exposing phosphatidylcholine on the outer leaflet and contributing to events such as membrane remodeling and cell activation. The process is distinct from ATP-dependent flippases and is instead driven by calcium-activated scramblases, most notably TMEM16F. Researchers study this term because it sits at the intersection of membrane biology, hemostasis, and cell signaling, and because its dysregulation is linked to bleeding disorders and other pathologies. Understanding the molecular players and regulatory logic of phosphatidylcholine scrambling is therefore critical for both basic membrane biology and translational research.
calcium activated phosphatidylcholine scrambling At A Glance
| GO ID | GO:0061590 |
|---|---|
| GO term | calcium activated phosphatidylcholine scrambling |
| Ontology | biological_process |
| Synonym | none |
| Major function | Calcium-triggered transbilayer movement of phosphatidylcholine across the plasma membrane |
| Cellular location | Plasma membrane |
| Stimulus | Calcium ions |
| Key protein | TMEM16F (ANO6) |
| Related disorder | Scott syndrome |
What Is GO:0061590?
According to the Gene Ontology, GO:0061590 is defined as the movement of a population of phosphatidylcholine molecules from one leaflet of the plasma membrane bilayer to the opposite leaflet as a result of a calcium stimulus. In other words, it is a calcium-dependent, bidirectional transbilayer redistribution of phosphatidylcholine that disrupts the normal asymmetric phospholipid arrangement of the plasma membrane.
Why Is calcium activated phosphatidylcholine scrambling Important in Cell Biology?
Calcium activated phosphatidylcholine scrambling is important because it represents a fundamental mechanism by which cells rapidly remodel their plasma membrane in response to calcium signals. This process contributes to the exposure of phospholipids that serve as signaling platforms and is mechanistically linked to phosphatidylserine exposure, which is critical for blood coagulation and cell clearance. Because TMEM16F is a principal mediator, mutations in this protein cause Scott syndrome, a bleeding disorder characterized by defective calcium-induced phospholipid scrambling. Moreover, the same process influences membrane curvature, vesicle budding, and cell fusion events, making it relevant to immunology, hematology, and cancer biology.
• Provides a calcium-dependent mechanism for collapsing plasma membrane phospholipid asymmetry.
• Enables exposure of phosphatidylcholine and other phospholipids on the cell surface during activation.
• Is required for normal hemostasis through its role in phosphatidylserine exposure and coagulation.
• Mutations in TMEM16F cause Scott syndrome, a rare inherited bleeding disorder.
• Contributes to platelet and lymphocyte activation responses.
• Can be measured quantitatively using fluorescent phospholipid analogs and cell-based assays.
• Serves as a paradigm for calcium-activated lipid transport at the plasma membrane.
• Is a target for CRISPR-based functional dissection of scramblase genes.
• Links membrane lipid dynamics to cell signaling and immune recognition.
• Has potential relevance in cancer biology through altered membrane lipid organization.
What Happens During calcium activated phosphatidylcholine scrambling?
Calcium binding and scramblase activation
In simple terms: Calcium ions bind to a scramblase protein and switch it on.
The process begins when intracellular calcium levels rise and calcium ions bind to a calcium-activated scramblase such as TMEM16F at the plasma membrane. This binding triggers a conformational change that opens a lipid-conducting pathway, allowing phospholipids to move between leaflets. Studies in platelets and erythrocytes have shown that calcium elevation is both necessary and sufficient to induce transbilayer scrambling of fluorescent phospholipid analogs. The calcium sensitivity of this process has been characterized in human red cell ghosts, where scrambling occurs at physiologically relevant calcium concentrations.
Transbilayer movement of phosphatidylcholine
In simple terms: Phosphatidylcholine molecules flip from one side of the membrane to the other.
Once activated, the scramblase facilitates the movement of phosphatidylcholine molecules from one leaflet of the plasma membrane bilayer to the opposite leaflet. This movement is bidirectional and does not require ATP, distinguishing it from flippase-mediated transport. Cell-based scrambling assays using fluorescent phosphatidylcholine analogs have demonstrated that TMEM16F exhibits headgroup preference, with measurable differences in the transport of various phospholipid species. The process results in a loss of the normal asymmetric distribution of phosphatidylcholine across the bilayer.
Loss of membrane phospholipid asymmetry
In simple terms: The membrane becomes less organized, with lipids appearing on both sides.
As phosphatidylcholine scrambles across the bilayer, the previously asymmetric distribution of phospholipids is disrupted. This loss of asymmetry is a hallmark of activated platelets and erythrocytes and is observed in lymphocytes following calcium-dependent stimulation. The complex of phosphatidylinositol 4,5-bisphosphate and calcium ions is not responsible for calcium-induced loss of phospholipid asymmetry in human erythrocytes, as shown in studies of Scott syndrome cells. This indicates that a distinct protein-mediated scrambling mechanism, rather than simple lipid-calcium interactions, drives the process.
Physiological consequences and downstream signaling
In simple terms: The scrambled membrane sends signals and triggers cellular responses.
Exposure of phosphatidylcholine and other phospholipids on the outer leaflet has functional consequences for cell signaling, coagulation, and cell-cell interactions. In Scott syndrome, defective calcium-induced phospholipid scrambling leads to impaired thrombin generation and a bleeding phenotype. The process is also implicated in membrane remodeling events such as microvesicle shedding and cell fusion. Because TMEM16F is broadly expressed, calcium-activated phosphatidylcholine scrambling may influence diverse physiological contexts beyond hemostasis.
Key Genes Involved in GO:0061590 calcium activated phosphatidylcholine scrambling
The following genes and proteins have been experimentally linked to calcium-activated phosphatidylcholine scrambling or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TMEM16F (ANO6) | Calcium-activated phospholipid scramblase | Primary mediator of phosphatidylcholine scrambling; mutated in Scott syndrome |
| TMEM16A (ANO1) | Calcium-activated chloride channel | Related TMEM16 family member used for comparative studies |
| TMEM16B (ANO2) | Calcium-activated chloride channel | Family member with distinct ion transport function |
| XKR8 | Phospholipid scramblase | Apoptosis-associated scramblase with different regulation |
| PLSCR1 | Phospholipid scramblase | Proposed scramblase with debated calcium dependence |
| PLSCR2 | Phospholipid scramblase | Family member studied in lymphocytes |
| PLSCR3 | Phospholipid scramblase | Family member with proposed roles in lipid scrambling |
| PLSCR4 | Phospholipid scramblase | Family member with proposed roles in lipid scrambling |
| ATP11A | Flippase | Maintains phospholipid asymmetry; opposes scrambling |
| ATP11C | Flippase | Maintains phospholipid asymmetry; opposes scrambling |
| TMEM16F variants | Disease-associated mutants | Used to model Scott syndrome and assess calcium sensitivity |
| ANO6 splice variants | Alternatively spliced isoforms | May modulate scramblase activity |
| PIP2 | Signaling lipid | Proposed regulator of scramblase activity |
| Calmodulin | Calcium sensor | Potential modulator of calcium-dependent scrambling |
| TMEM16F in platelets | Platelet scramblase | Required for phosphatidylserine exposure and coagulation |
| TMEM16F in lymphocytes | Lymphocyte scramblase | Contributes to calcium-induced scrambling in immune cells |
| TMEM16F in erythrocytes | Erythrocyte scramblase | Studied in red cell ghosts for calcium sensitivity |
| TMEM16F in thymoma | Potential target | Gene expression alterations in thymoma include membrane-related genes |
How Is calcium activated phosphatidylcholine scrambling Regulated?
Calcium-activated phosphatidylcholine scrambling is regulated primarily by intracellular calcium concentration and the availability of functional scramblase proteins at the plasma membrane. The process is independent of ATP and does not require phosphatidylinositol 4,5-bisphosphate-calcium complexes, as demonstrated in Scott syndrome erythrocytes. TMEM16F activity can be modulated by its lipid environment and by disease-associated mutations that alter calcium sensitivity or protein stability. In lymphocytes, multiple activation pathways converge on calcium-dependent scrambling, suggesting integration with immune signaling cascades. The opposing action of ATP-dependent flippases such as ATP11A and ATP11C helps maintain membrane asymmetry under resting conditions, and their downregulation or inactivation permits scrambling to dominate.
calcium activated phosphatidylcholine scrambling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TMEM16F (ANO6) | Scott syndrome | Knockout and point-mutation cell lines |
| TMEM16F (ANO6) | Platelet dysfunction | Platelet-like cell models with KO |
| TMEM16F (ANO6) | Lymphocyte activation defects | Jurkat or primary lymphocyte KO |
| ATP11A/ATP11C | Membrane asymmetry disorders | Knockout to assess flippase-scramblase balance |
| PLSCR family | Apoptosis and immune signaling | Overexpression and KO models |
Scott syndrome and bleeding disorders
Scott syndrome is a rare inherited bleeding disorder caused by defective calcium-induced phospholipid scrambling. Patients with Scott syndrome have impaired phosphatidylserine exposure on activated platelets and erythrocytes, leading to reduced thrombin generation and a bleeding tendency. Studies using Scott syndrome erythrocytes demonstrated that the complex of phosphatidylinositol 4,5-bisphosphate and calcium ions is not responsible for the loss of phospholipid asymmetry, pointing to a protein-mediated defect. Mutations in TMEM16F have been identified as a cause of Scott syndrome, establishing the gene as essential for calcium-activated phosphatidylcholine scrambling.
Platelet and lymphocyte activation
Calcium-activated phosphatidylcholine scrambling is a feature of activated platelets and lymphocytes. In platelets, this process contributes to the surface exposure of phospholipids required for coagulation factor assembly. In lymphocytes, calcium-dependent scrambling pathways have been characterized, linking membrane lipid dynamics to immune cell activation. Defects in this process can therefore affect both hemostasis and immune responses.
Cancer and membrane lipid remodeling
Alterations in membrane lipid organization and scramblase expression have been observed in cancer contexts, including thymoma, where gene expression profiling revealed changes in membrane-related genes. While direct evidence linking GO:0061590 to cancer remains limited, the broader role of phospholipid scrambling in cell survival, apoptosis, and immune recognition suggests potential relevance. Further research using CRISPR models is needed to clarify whether calcium-activated phosphatidylcholine scrambling contributes to tumor biology.
From calcium activated phosphatidylcholine scrambling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is TMEM16F required for calcium-activated phosphatidylcholine scrambling? | TMEM16F knockout cell line |
| Does a specific TMEM16F mutation alter calcium sensitivity? | Point-mutation knock-in of disease variants |
| Can a tagged TMEM16F be used to track localization during scrambling? | Tagged knock-in (e.g., GFP or HA) |
| Does overexpression of PLSCR1 enhance scrambling? | Overexpression cell line |
| What is the headgroup preference of TMEM16F? | Cell-based scrambling assay with fluorescent lipids |
| How do flippases oppose scramblase activity? | ATP11A/ATP11C knockout or knockdown |
How to Study the calcium activated phosphatidylcholine scrambling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorescent phospholipid scrambling assay | Transbilayer movement of phosphatidylcholine analogs | Quantifying scramblase activity |
| Calcium imaging | Intracellular calcium concentration | Confirming calcium trigger |
| CRISPR knockout | Loss-of-function effect on scrambling | Testing TMEM16F requirement |
| Point-mutation knock-in | Effect of disease variants | Modeling Scott syndrome |
| Lipidomics | Phospholipid distribution | Global membrane remodeling |
| Flow cytometry | Surface exposure of phospholipids | Platelet and lymphocyte activation |
| Red cell ghost assay | Calcium sensitivity of scrambling | Biochemical dissection |
| Live-cell imaging | Real-time lipid movement | Dynamic studies of scramblase activity |
Cell-based scrambling assays
Cell-based scrambling assays using fluorescent phospholipid analogs are the gold standard for measuring calcium-activated phosphatidylcholine scrambling. These assays typically label the outer leaflet with a fluorescent phosphatidylcholine probe and monitor its movement to the inner leaflet or vice versa after calcium stimulation. The method allows quantitative assessment of headgroup preference and calcium sensitivity.
Calcium imaging and manipulation
Because the process is calcium-dependent, researchers use calcium ionophores or receptor agonists to raise intracellular calcium and trigger scrambling. Calcium imaging with fluorescent indicators can confirm that calcium elevation precedes lipid scrambling. Red cell ghost preparations have been particularly useful for controlling calcium concentrations precisely.
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, and knock-in approaches enable causal testing of candidate scramblase genes. Knockout of TMEM16F abolishes calcium-activated phosphatidylcholine scrambling, while point mutations can mimic Scott syndrome variants. These models are essential for linking genotype to lipid transport phenotype.
Biochemical and lipidomic analysis
Lipidomic profiling and biochemical assays can quantify changes in phospholipid distribution across membrane leaflets. These methods complement cell-based assays by providing a global view of lipid remodeling. In lymphocytes, such approaches have helped define activation pathways that lead to scrambling.
How CRISPR Can Be Used to Study GO:0061590 calcium activated phosphatidylcholine scrambling
Knockout
CRISPR knockout of TMEM16F or related scramblase genes is used to test whether a candidate gene is required for calcium-activated phosphatidylcholine scrambling. Knockout cell lines show loss of calcium-induced lipid movement, providing causal evidence. This approach is also useful for eliminating flippase genes to study their opposing roles.
Point Mutation
Point-mutation knock-in models allow researchers to introduce disease-associated variants, such as those found in Scott syndrome, into the endogenous TMEM16F locus. These models help determine how specific amino acid changes alter calcium sensitivity, protein stability, or lipid transport activity.
Knock-in
Tagged knock-in of TMEM16F with fluorescent or epitope tags enables real-time tracking of protein localization and dynamics during scrambling. Knock-in of reporter constructs can also be used to monitor transcriptional regulation of scramblase genes.
Overexpression
Overexpression of TMEM16F or other candidate scramblases can enhance calcium-activated phosphatidylcholine scrambling and is used to test gain-of-function effects. Overexpression models are particularly useful for studying headgroup preference and for screening chemical modulators.
How EDITGENE Supports calcium activated phosphatidylcholine scrambling Research
Researchers studying calcium activated phosphatidylcholine scrambling-related genes often need to determine whether a candidate gene is causally involved in lipid transport, membrane asymmetry, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for calcium activated phosphatidylcholine scrambling research.
Frequently Asked Questions About calcium activated phosphatidylcholine scrambling
What is calcium activated phosphatidylcholine scrambling?
It is the calcium-triggered movement of phosphatidylcholine molecules from one leaflet of the plasma membrane to the opposite leaflet, as defined by GO:0061590.
What genes are involved in calcium activated phosphatidylcholine scrambling?
TMEM16F (ANO6) is the principal gene, with additional roles for PLSCR family members, ATP11A, and ATP11C.
What is the role of TMEM16F in phosphatidylcholine scrambling?
TMEM16F is a calcium-activated scramblase that facilitates transbilayer phosphatidylcholine movement and is mutated in Scott syndrome.
How is calcium activated phosphatidylcholine scrambling measured?
It is measured using cell-based assays with fluorescent phospholipid analogs, calcium imaging, and lipidomics.
What diseases are associated with defective phosphatidylcholine scrambling?
Scott syndrome, a rare bleeding disorder, is caused by defective calcium-induced phospholipid scrambling due to TMEM16F mutations.
Is phosphatidylcholine scrambling ATP-dependent?
No, calcium-activated phosphatidylcholine scrambling is ATP-independent and distinct from flippase-mediated transport.
What is the difference between scramblase and flippase?
Scramblases promote bidirectional transbilayer lipid movement, while flippases use ATP to maintain phospholipid asymmetry.
Can CRISPR be used to study phosphatidylcholine scrambling?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to dissect scramblase gene function.
What is Scott syndrome?
Scott syndrome is a rare inherited bleeding disorder characterized by defective calcium-induced phospholipid scrambling and impaired thrombin generation.
Which cell types exhibit calcium activated phosphatidylcholine scrambling?
Platelets, erythrocytes, and lymphocytes are well-characterized cell types that exhibit this process.
Conclusion
Calcium activated phosphatidylcholine scrambling (GO:0061590) is a fundamental calcium-dependent membrane process mediated primarily by TMEM16F and related scramblases. It disrupts phospholipid asymmetry, contributes to platelet and lymphocyte activation, and is defective in Scott syndrome. Continued research using CRISPR-engineered cell models and quantitative scrambling assays will further clarify its molecular regulation and therapeutic potential.
References
- 1. Teo CF et al.. 2025. A cell-based scrambling assay reveals the phospholipid headgroup preference of TMEM16F on the plasma membrane.. Proc Natl Acad Sci U S A 122(44):e2516822122 PMID: 41166415
- 2. Suzuki J et al.. 2014. Phospholipid scrambling on the plasma membrane.. Methods Enzymol 544:381-93 PMID: 24974298
- 3. Smeets EF et al.. 1994. Calcium-induced transbilayer scrambling of fluorescent phospholipid analogs in platelets and erythrocytes.. Biochim Biophys Acta 1195(2):281-6 PMID: 7947922
- 4. Teo CF et al.. 2025. A cell-based scrambling assay reveals phospholipid headgroup preference of TMEM16F on the plasma membrane.. bioRxiv PMID: 40667283
- 5. Meng FJ et al.. 2019. Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets.. Thorac Cancer 10(5):1129-1135 PMID: 30932350
- 6. Williamson P et al.. 2001. Phospholipid scramblase activation pathways in lymphocytes.. Biochemistry 40(27):8065-72 PMID: 11434775
- 7. Woon LA et al.. 1999. Ca2+ sensitivity of phospholipid scrambling in human red cell ghosts.. Cell Calcium 25(4):313-20 PMID: 10456228
- 8. Bevers EM et al.. 1995. The complex of phosphatidylinositol 4,5-bisphosphate and calcium ions is not responsible for Ca2+-induced loss of phospholipid asymmetry in the human erythrocyte: a study in Scott syndrome, a disorder of calcium-induced phospholipid scrambling.. Blood 86(5):1983-91 PMID: 7655025
